Innovating Works

SPRM SOCIEDADE PORTUGUESA DE RESSONANCI...

BETA3_LVH: A multi center randomized placebo controlled trial of mirabegron a new beta3 adrenergic receptor a... SPRM SOCIEDADE PORTUGUESA DE RESSONANCIA MAGNETICA SA participó en un H2020: H2020-PHC-2014-2015 Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fra...
2015-04-15 - 2022-08-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.